Una aproximación al modelo corporal de santidad contrarreformista a través de la vida de Juana de la Cruz y otras santas franciscanas

Suárez, Pedro García

doi:10.30827/arenal.v28i2.8812

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a European study that assessed COVID-19 severity and morality in 697 patients with hematologic malignant neoplasms, a 33% mortality rate was observed and higher rates of severe disease and death in patients with leukemia were reported. 32 In the present study, among patients with solid tumors, those with lung, gastrointestinal (noncolorectal), and central nervous system tumors had worse outcomes. Higher mortality and increased risk of severe COVID-19 infection have been reported in patients with lung cancer.…”

Section: Discussionmentioning

confidence: 54%

Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer

et al. 2022

View full text Add to dashboard Cite

As the COVID-19 pandemic continues, understanding the clinical outcomes of patients with cancer and COVID-19 has become critically important.OBJECTIVE To compare the outcomes of patients with or without cancer who were diagnosed with COVID-19 and to identify the factors associated with mortality, mechanical ventilation, intensive care unit (ICU) stay, and hospitalization. DESIGN, SETTING, AND PARTICIPANTSThis cohort study obtained data from the Optum de-identified COVID-19 electronic health record data set. More than 500 000 US adults who were diagnosed with COVID-19 from January 1 to December 31, 2020, were analyzed.EXPOSURES The patient groups were (1) patients without cancer, (2) patients with no recent cancer treatment, and (3) patients with recent cancer treatment (within 3 months before COVID-19 diagnosis) consisting of radiation therapy or systemic therapy.MAIN OUTCOMES AND MEASURES Mortality, mechanical ventilation, ICU stay, and hospitalization within 30 days of COVID-19 diagnosis were the main outcomes. Unadjusted rates and adjusted odds ratios (ORs) of adverse outcomes were presented according to exposure group.RESULTS A total of 507 307 patients with COVID-19 were identified (mean [SD] age, 48.4 [18.4] years; 281 165 women [55.4%]), of whom 493 020 (97.2%) did not have cancer. Among the 14 287 (2.8%) patients with cancer, 9991 (69.9%) did not receive recent treatment and 4296 (30.1%) received recent treatment. In unadjusted analyses, patients with cancer, regardless of recent treatment received, were more likely to have adverse outcomes compared with patients without cancer (eg, mortality rate: 1.6% for patients without cancer, 5.0% for patients with no recent cancer treatment, and 7.8% for patients with recent cancer treatment). After adjustment, patients with no recent cancer treatment had similar or better outcomes than patients without cancer (eg, mortality OR, 0.93 [95% CI, 0.84-1.02]; mechanical ventilation OR, 0.61 [95% CI, 0.54-0.68]). In contrast, a higher risk of death (OR, 1.74; 95% CI, 1.54-1.96), ICU stay (OR, 1.69; 95% CI, 1.54-1.87), and hospitalization (OR, 1.19; 95% CI, 1.11-1.27) was observed in patients with recent cancer treatment. Compared with patients with nonmetastatic solid tumors, those with metastatic solid tumors and hematologic malignant neoplasms had worse outcomes (eg, mortality OR, 2.36 [95% CI,; mechanical ventilation OR, 0.87 [95% CI, 0.70-1.08]). Recent chemotherapy and chemoimmunotherapy were also associated with worse outcomes (eg, chemotherapy mortality OR, 1.84 [95% CI, 1.51-2.26]).CONCLUSIONS AND RELEVANCE This cohort study found that patients with recent cancer treatment and COVID-19 had a significantly higher risk of adverse outcomes, and patients with no recent cancer treatment had similar outcomes to those without cancer. The findings have risk stratification and resource use implications for patients, clinicians, and health systems.

show abstract

Section: Discussionmentioning

confidence: 54%

Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…COVID-19, which is due to infection with SARS-CoV-2, results in poor outcomes in patients with hematologic cancers (approximately 40% mortality rate). 1,2 The efficacy of anti-SARS-CoV-2 mRNA vaccines has been successfully demonstrated in healthy populations 3 and also has been reported in immunocompromised patients. Recently, we showed that a first injection of the BNT162b2 (Pfizer-BioNTech) vaccine induced an antibody response in 55% of 112 allogeneic hematopoietic stem cell transplant (HSCT) recipients.…”

Section: Introductionmentioning

confidence: 98%

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Bourgeois

Coste‐Burel²,

Guillaume

et al. 2021

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

Una aproximación al modelo corporal de santidad contrarreformista a través de la vida de Juana de la Cruz y otras santas franciscanas

Cited by 2 publications

References 0 publications

Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer

Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Contact Info

Product

Resources

About